Taken together, our data demonstrate that our MSSs are able to predict response to MAPKi in vivo specifically, regardless of the natural course of tumor progression, and that they outperform the MPAS to predict sensitivity to BRAFi Type I 1/2 and MEK1/2i. The gene discussed is MAP2K1; the disease is neoplasm.